Blood platelet disease
MONDO:0002245Disorders caused by abnormalities in platelet count or function.
Also known as: platelet abnormality, platelet disorder, thrombocytopathy
358 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can Mountain-Like workouts help fatty liver? small trial aims to find out
Disease control CompletedThis study tests whether aerobic exercise in simulated altitude (normobaric hypoxia) can improve body composition and metabolism in people with MASLD, a type of fatty liver disease. Twenty sedentary adults with MASLD will walk on a treadmill for 8 weeks, either in mild altitude o…
Phase: NA • Sponsor: University of Trieste • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could a 5-Day drug course make surgery safer for liver patients with low platelets?
Disease control CompletedThis study tests whether a 5-day course of avatricopal can safely raise platelet counts in people with chronic liver disease who have low platelets and need surgery. The goal is to see if more patients reach a platelet count of at least 50×10⁹/L on the day of their procedure, whi…
Sponsor: Beijing Ditan Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental MegaLT injection targets dangerous low platelets in early trial
Disease control CompletedThis early-phase trial tests a new cell therapy called MegaLT for people with dangerously low platelet counts that don't improve after radiation, chemotherapy, or stem cell transplant. Only 10 participants will receive the injection at different doses to check safety and how the …
Phase: PHASE1 • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a lower dose of an old antibiotic tame Drug-Resistant TB?
Disease control CompletedThis study tests whether a low daily dose of the antibiotic linezolid, added to a personalized combination of other drugs, is safe and tolerable for people with multidrug-resistant tuberculosis (MDR-TB). Participants take either linezolid or a placebo for 16 weeks, alongside thei…
Phase: PHASE1, PHASE2 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug strategy may reduce blood transfusions after organ transplants
Disease control CompletedThis study looked at whether giving romiplostim, a drug that boosts platelet production, could reduce the need for platelet transfusions in patients with low platelet counts after heart or lung transplantation or use of heart/lung support devices. Researchers compared a group of …
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with bleeding disorder: drug boosts platelets in phase 3 trial
Disease control CompletedThis study tested a medication called avatrombopag in 75 children aged 1 to 17 with immune thrombocytopenia (ITP) lasting at least 6 months. ITP is a condition where the immune system destroys platelets, raising the risk of bruising and bleeding. The goal was to see if the drug c…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for low platelets: avatrombopag tested in japanese ITP patients
Disease control CompletedThis study tested a drug called avatrombopag in 19 Japanese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal was to see if the drug could safely increase platelet counts over 26 weeks. Parti…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug may offer longer-lasting bleed control for rare platelet disorder
Disease control CompletedThis lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug may help liver transplant patients avoid bleeding complications
Disease control CompletedThis study looked at whether the drug avatrombopag can safely and effectively raise platelet counts in people who develop dangerously low platelets after a liver transplant. Researchers compared 67 patients who received the drug with 67 similar patients who got standard care. The…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill shows promise for rare blood disorder
Disease control CompletedThis study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could help adults with low platelet disorder
Disease control CompletedThis Phase 3 trial tested an oral drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants who had not responded well to prior treatments received eith…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedThis study tested a new medicine called HBM9161, given as a weekly shot under the skin, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising the risk of bleeding. The trial included 36 people who had not responded…
Phase: PHASE2, PHASE3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a daily pill boost blood counts in aplastic anemia?
Disease control CompletedThis study tested the drug eltrombopag in 34 people with moderate aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Eltrombopag is a pill that mimics a natural protein to stimulate blood cell production. Researchers measured whether it safely imp…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a platelet booster keep chemo on track for lymphoma patients?
Disease control CompletedThis phase 2 study tested whether the drug romiplostim can prevent severe low platelet counts caused by chemotherapy in people with lymphoma. Eleven adult patients received weekly injections of romiplostim during their 21-day chemo cycles. The goal was to see if it could reduce t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug shows promise for Long-Term platelet control in rare bleeding disorder
Disease control CompletedThis phase 3 trial tested the long-term safety and effectiveness of efgartigimod, an IV drug, in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants received efgartigimod infusions over 52 w…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New transplant cocktail aims to cut complications in bone marrow failure
Disease control CompletedThis phase 2 trial tested a combination of treosulfan, fludarabine, and rabbit antithymocyte globulin before a bone marrow transplant in 40 people with bone marrow failure diseases like Diamond-Blackfan anemia and Shwachman-Diamond syndrome. The goal was to see if this conditioni…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cell therapy offers hope for Hard-to-Treat blood disorder
Disease control CompletedThis early-phase study tested a new cell therapy called YTS109 in 7 people with a severe type of autoimmune anemia that did not get better after at least 3 other treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the dise…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill shows promise for rare bleeding disorder
Disease control CompletedThis study tested an experimental oral drug called rilzabrutinib in 86 adults with relapsed immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The drug aims to block a key immune signal to help raise platelet counts. The …
Phase: PHASE2 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for bleeding risk in hepatitis b patients?
Disease control CompletedThis study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Low-Dose rituximab shows promise for blood disorder
Disease control CompletedThis study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition causing low platelet counts and bleeding. The goal was to see which regimen better raises platelets and controls bleeding. Participants had failed or relapsed on stand…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a transplant drug tame tough vascular birthmarks?
Disease control CompletedThis phase 2 trial tested the drug sirolimus (rapamycin) in 61 children and young adults with complicated vascular anomalies—abnormal blood vessel growths that can cause pain, bleeding, or organ problems. The goal was to see if sirolimus could safely shrink these anomalies and im…
Phase: PHASE2 • Sponsor: Denise Martin Adams • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Breakthrough drug combo may replace plasma exchange for rare blood disease
Disease control CompletedThis study tested whether a drug called caplacizumab, combined with immune-suppressing medicines, could treat a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual plasma exchange procedure. Fifty-one adults aged 18 to …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for ITP patients: drug boosts platelet counts in early study
Disease control CompletedThis study tested a drug called lusutrombopag in 17 Chinese adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants had failed standard treatments and took the drug for up to 12 w…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Drug may help bone marrow failure patients recover faster after transplant
Disease control CompletedThis study tested a drug called eltrombopag in 118 people with bone marrow failure who had a stem cell transplant. The goal was to see if the drug could help their platelet levels recover faster after the transplant. Platelets are blood cells that help stop bleeding, and slow rec…
Phase: PHASE2, PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Protein powder during fasting may save your muscles while you shed pounds
Disease control CompletedThis study looked at whether taking a protein supplement on fasting days during a 4-week alternate-day fasting program could help young men with overweight lose fat while keeping muscle. Twenty-six men aged 21 to 35 either ate a small meal (400-600 kcal) or the same meal plus a w…
Phase: NA • Sponsor: Nanyang Technological University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smart dosing keeps chemo on track for GI cancer patients
Disease control CompletedThis study tested a doctor-designed dose adjustment algorithm to prevent unplanned delays in FOLFOX chemotherapy for people with cancers of the colon, stomach, esophagus, and other digestive organs. 52 adults participated, and the goal was to see if the algorithm could keep treat…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New pill shows promise for rare blood cancer in early trial
Disease control CompletedThis early-phase trial tested a new drug called flonoltinib maleate in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow cancers. The main goals were to check safety, find the right dose, and see how the body processes the drug. Researchers hope this drug…
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug shows promise in preventing deadly blood clot relapses in japanese patients
Disease control CompletedThis study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goa…
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Bomedemstat extension trial tests Long-Term safety for blood cancer patients
Disease control CompletedThis study looks at the long-term safety of bomedemstat, an oral drug, in 81 people with myeloproliferative neoplasms (MPNs) like essential thrombocythemia and primary myelofibrosis. Participants had already taken bomedemstat in a prior study. Researchers tracked side effects, sp…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug BIVV020 shows promise for chronic ITP in small trial
Disease control CompletedThis phase 2a trial tested the drug BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The main goal was to see if BIVV020 could help maintain a safe platelet count over tim…
Phase: PHASE2 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:24 UTC
-
New combo therapy shows promise for Steroid-Resistant ITP
Disease control CompletedThis completed phase 3 trial tested whether adding all-trans retinoic acid (ATRA) to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) that did not respond to steroids. The study enrolled 96 participants and measured sustained platelet …
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:57 UTC
-
New drug itacitinib tested for Hard-to-Treat myelofibrosis
Disease control CompletedThis phase 2 study tested the drug itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and find the right dose, and to see if it could shrink an enlarged sple…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 13:11 UTC
-
Stomach bug treatment may boost blood platelets in ITP patients
Disease control CompletedThis study looked at whether treating Helicobacter pylori (a common stomach infection) with antibiotics can raise platelet counts in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. Researchers enrol…
Phase: NA • Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
New imaging method could speed up diagnosis of blood clotting disorders
Diagnosis CompletedThis study tested a new diagnostic tool that uses imaging flow cytometry to examine platelets in blood samples. Researchers compared it to standard lab tests in 31 patients suspected of having platelet disorders or heparin-induced thrombocytopenia. The goal was to see if the new …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could unmask hidden bleeding disorders
Diagnosis CompletedThis study tested a new lab method to diagnose platelet function disorders in 322 people with bleeding symptoms. The method uses flow cytometry to detect signaling defects in platelets, which are often missed by standard tests. The goal was to standardize the technique across mul…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Can your own fat help heal scars?
Symptom relief CompletedThis study tests whether a single injection of nanofat—made from a person's own fat—can improve the appearance of atrophic scars caused by burns or trauma. Each participant has two similar scars: one gets the nanofat injection plus silicone gel, and the other gets only silicone g…
Phase: NA • Sponsor: Benha University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Itch relief showdown: which drug stops water-induced agony?
Symptom relief CompletedThis study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Can a global patient registry unlock the secrets of a rare muscle disease?
Knowledge-focused CompletedThis study is building an international registry of people with GNE myopathy, an ultra-rare muscle disease that causes progressive weakness and often leads to wheelchair use. Participants will complete online questionnaires about their symptoms, medical history, quality of life, …
Sponsor: Newcastle University • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
New blood test could help patients who Don't respond to platelet transfusions
Knowledge-focused CompletedThis study looked at 68 people with low platelet counts who had become resistant to platelet transfusions due to HLA antibodies. Researchers tested a new lab method (C1q binding) on stored blood samples to see if it could better predict whether a transfusion would work compared t…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can Ultra-Processed foods make you eat more? a study investigates
Knowledge-focused CompletedThis study aims to understand how ultra-processed foods affect energy metabolism compared to unprocessed foods. Healthy adults aged 18-60 will stay at a research center for four weeks, eating different diets each week. Researchers will measure how much they eat, their metabolic r…
Phase: NA • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a platelet-boosting drug shorten recovery after stem cell transplants?
Knowledge-focused CompletedThis study looks back at medical records of people who had an allogeneic stem cell transplant to see whether romiplostim helped their platelets recover faster. Platelets are blood cells that help clotting, and low counts are common after transplant. The researchers will compare p…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can your genes predict blood thinner effectiveness?
Knowledge-focused CompletedThis trial investigates whether genetic variations in the CES1 gene influence how the body responds to the blood thinners clopidogrel and aspirin. Healthy Amish adults will take clopidogrel for a week, then a single dose of aspirin, with blood tests measuring platelet function be…
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Scientists track rare muscle disease to unlock its secrets
Knowledge-focused CompletedThis study followed 78 people with GNE myopathy, a rare genetic disease that causes progressive muscle weakness starting in young adulthood. Researchers collected medical history, blood samples, and muscle function tests over up to two years to understand how the disease progress…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Your DNA could determine which heart drug works best
Knowledge-focused CompletedThis trial investigates whether a common genetic variation in the CES1 gene affects how the body processes two antiplatelet drugs, clopidogrel and ticagrelor. Healthy volunteers of Amish descent will take each drug for eight days in a crossover design, and researchers will measur…
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Scientists hunt for genetic roots of rare childhood blood disorder
Knowledge-focused CompletedThis study investigates the genetic causes of pediatric Evans syndrome, a rare autoimmune condition where the immune system attacks blood cells. Researchers analyze blood samples from affected children and their families to find known or new mutations. The goal is to better under…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Scientists hunt for hidden genetic causes of rare bleeding disorder
Knowledge-focused CompletedThis study investigates inherited thrombocytopenias, rare conditions where low platelet counts cause bleeding problems. About half of patients have an unknown genetic cause. Researchers aim to identify new disease genes and build a lab-grown bone marrow model to test how well dru…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who will get chronic ITP?
Knowledge-focused CompletedThis completed study looked at blood samples from 70 children and adults newly diagnosed with immune thrombocytopenic purpura (ITP), a condition that causes easy bruising and bleeding. Researchers wanted to see if certain immune and blood markers could predict whether the disease…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare bleeding disorder study seeks to unlock antibody mystery
Knowledge-focused CompletedThis study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Could your diet trigger lupus? new study investigates
Knowledge-focused CompletedThis study measured phytoestrogens (plant-based compounds) in the blood and urine of 63 premenopausal women with active lupus, other autoimmune diseases, or no disease. Researchers also asked about diet and measured estradiol levels. The goal was to see if these dietary compounds…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Heart-Lung machine showdown: which oxygenator spares your platelets?
Knowledge-focused CompletedThis study looked at 68 adults having planned heart surgery that required a heart-lung machine. Researchers compared two different oxygenators (artificial lungs) to see if one caused more damage to platelets, the blood cells that help stop bleeding. They used a special test calle…
Phase: NA • Sponsor: BRADEN DULONG • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
HELLP syndrome blood markers tracked daily in new study
Knowledge-focused CompletedThis completed study observed 72 pregnant women with HELLP syndrome in the ICU. Researchers tracked daily changes in platelets, liver enzymes, and lactate dehydrogenase before and after delivery. The goal was to understand how these biological markers evolve, not to test a treatm…
Sponsor: CHU Mohammed VI Marrakech • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Study sheds light on hidden cause of unexplained bleeding
Knowledge-focused CompletedThis study looked at 166 people with unexplained bleeding to find out how many have problems with tiny granules inside their platelets. These granules help blood clot. The researchers measured granule number, content, and release, and checked if these defects were linked to bleed…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New tests could help spot hidden blood disorder in seniors
Knowledge-focused CompletedThis study followed 37 adults over age 60 with unexplained low platelet counts to see if certain tests could predict immune thrombocytopenic purpura (ITP). Participants had blood tests, bone marrow biopsies, and a short course of the steroid prednisone. The goal was to find which…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Large study tracks antibody risk in pregnant women to prevent newborn bleeding
Knowledge-focused CompletedThis study followed over 14,000 pregnant women to see how many are at risk for a condition called FNAIT, where a mother's immune system attacks her baby's platelets, causing dangerous bleeding. Researchers measured how often women develop specific antibodies (HPA-1a) and looked a…
Sponsor: Rallybio • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
THC sleep study: frequent vs. rare users under the microscope
Knowledge-focused CompletedThis study looked at how a pill form of THC (dronabinol) affects sleep and thinking in 18 adults. Some participants used cannabis frequently (more than 3 times a week), while others rarely used it (less than 10 times ever). Researchers measured sleep stages, alertness, memory, an…
Phase: EARLY_PHASE1 • Sponsor: Oregon Health and Science University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Could cancer trick the body into attacking its own platelets?
Knowledge-focused CompletedThis study looked at 33 adults who had both immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — and cancer. Researchers wanted to see if treating the cancer could also improve ITP. They also investigated whether cancer cells might mimic platel…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
ITP study reveals hidden toll on brain and body
Knowledge-focused CompletedThis study looked at how chronic immune thrombocytopenia (ITP) affects thinking skills and fatigue in adults. Researchers measured brain function and inflammation using blood tests and questionnaires in 97 patients. The goal was to better understand these connections, not to test…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
New blood test may reduce bleeding and clotting in life support patients
Knowledge-focused CompletedThis study tested whether a blood test called thromboelastography (TEG) can better guide blood-thinning treatment in 61 patients on ECMO life support. ECMO patients face serious risks from bleeding or clotting, and current monitoring methods are not very reliable. Researchers com…
Sponsor: Damian Ratano • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists crack the code on failed platelet transfusions
Knowledge-focused CompletedThis study looked at 50 adults with severe low platelet counts who needed platelet transfusions. Researchers wanted to understand why some patients stop responding to these life-saving transfusions. They focused on antibodies that attack the donor platelets, aiming to find better…
Sponsor: Institut de cancérologie Strasbourg Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Can a simple blood test predict chemo side effects in brain cancer patients?
Knowledge-focused CompletedThis completed Phase 2 study looked at 244 glioblastoma patients to see if platelet counts during radiation and chemotherapy could predict who would develop dangerously low platelets later. The goal was to create a monitoring plan for high-risk patients. No new drug or treatment …
Phase: PHASE2 • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Tiny study asks: does aspirin work in patients with low platelets?
Knowledge-focused CompletedThis study looked at how well a daily low-dose aspirin works in people who have both immune thrombocytopenia (low platelets) and heart disease. Only 4 adults took part. Researchers measured platelet function after aspirin to see if the standard dose is enough to prevent blood clo…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Generic platelet drug put to the test: will it match the original?
Knowledge-focused CompletedThis study checked whether a generic eltrombopag olamine tablet works the same as the brand-name version in 36 healthy Chinese adults after a meal. Participants took a single dose of each formulation in random order, and researchers measured how the drug moved through their bodie…
Phase: NA • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New registry aims to unravel severe blood disorders in youth
Knowledge-focused CompletedThis completed registry study followed 80 children and young adults with severe immune cytopenias, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome. Researchers observed participants over up to 4 years to improve diagnosis and track the disease c…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Could your aspirin be failing you? trinidad study investigates
Knowledge-focused CompletedThis completed pilot study looked at whether some healthy adults are resistant to aspirin's blood-thinning effects. 48 participants took two different types of 81 mg aspirin for two weeks each, and their platelet function was measured. The goal was to understand how common aspiri…
Phase: PHASE2 • Sponsor: The University of The West Indies • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:41 UTC
-
Study reveals tricky platelet swings in blood disorder drug response
Knowledge-focused CompletedThis study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessar…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:26 UTC
-
New model may help decide which preterm babies need platelet transfusions
Knowledge-focused CompletedThis study looked at data from over 1000 preterm babies with low platelet counts to build a model that predicts their risk of major bleeding or death. The goal is to help doctors decide when a platelet transfusion is truly needed, since current guidelines based only on platelet c…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:13 UTC
-
Researchers collect blood from Low-Platelet patients to uncover clues
Knowledge-focused CompletedThis study collected one blood sample from 40 adults with very low platelets (30,000 or fewer per microliter) due to blood cancers or their treatments. The goal was simply to gather samples for research, not to test any new drug or therapy. Participants had to be 18 or older and …
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:23 UTC